Gastroesophageal Cancer | China In-Depth | China | 2024
China accounts for approximately half of the gastroesophageal cancer cases (including gastric, gastroesophageal junction, and esophageal cancer) in the world. Standard-of-care (SOC) treatments include perioperative chemotherapy for resectable patients and immunotherapy and biomarker-directed therapies for patients with metastatic disease. The gastroesophageal cancer therapy market in China is rapidly evolving and is expected to experience exponential growth over the next 10 years. This growth will largely be driven by the continued uptake of immune checkpoint inhibitors and the launch of first-in-class agents, such as Astella’s zolbetuximab and CARsgen’s CT041. In this report, we assess how clinical and nonclinical factors—price dynamics, inclusion in China’s National Reimbursement Drug List (NRDL)—will influence the launch and uptake of new therapies during the forecast period. Understanding the impact of these intersecting factors will be key to the success of current and future players in this highly lucrative market.
Questions answered
- What is the diagnosed incidence of gastroesophageal cancer in China, and how are patients treated today? Do treatment management strategies differ between urban and rural China?
- What are interviewed experts’ insights into current treatment options?
- What are the key unmet needs in the management of gastroesophageal cancer in China?
- What are the key market access considerations, and how are they likely to impact the uptake of emerging therapies in this market?
- What are the key drivers and constraints in the treatment of gastroesophageal cancer in China, and how will the therapy market evolve over the forecast period?
Content highlights
Primary research: Country-specific qualitative and quantitative insights driven by 5 thought-leader interviews and 75 surveys with medical oncologists. Supported by survey data collected for this and other Clarivate research.
Epidemiology: Diagnosed incidence of gastroesophageal cancer in urban versus rural China; clinically relevant and commercially relevant drug-treatable populations.
Forecast: 10-year, annualized, drug-level sales and patient share of key gastroesophageal cancer therapies through 2033, based on primary and secondary market research to formulate bottom-up assumptions.
Emerging therapies: Phase 3/ PR: 10+ drugs; Phase 2: 15+ drugs; coverage of select preclinical and Phase 1 products.
Product description
China In-Depth offers comprehensive market intelligence, including world-class epidemiology, keen insight into the China-specific access and reimbursement environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research. This solution helps companies gauge commercial outlooks and optimize clinical development, subpopulation targeting, physician messaging, and overall long-term strategy in China.
NEW: China In-Depth reports include a custom drug modeler. This tool enables clients to input their own assumptions for a drug and forecast three scenarios that can be directly compared with Clarivate’s projections for drugs included in the patient-based market forecast. To access the tool, download the Market Forecast Dashboard file on the Insights Platform.
